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Abstract
Purpose: TP53 is a tumor suppressor gene which participates in regulation of cellcycle check points, DNA repair, and apoptosis. The aim of this study was tocompare TP53 germ line gene polymorphisms (c.[215G>C]) wild – typehomozygotes GG with heterozygotes GC according to clinicopathological factors.
Methods: We reviewed the medical records of 87 (22% TP53 gene homozygotesand 78% heterozygotes) breast cancer patients who were diagnosed and treated inCOI in Gliwice. Polymorphism profile was assessed by RFLP-PCR technique.
Results: The presence of lobular invasive carcinoma was observed insignificantlymore often in homozygotes, especially in the group of patients at the age below 50years (29% vs. 4%, p = 0.095). Patients being TP53 gene heterozygotes had largertumor size (T > 2) than homozygotes (16% vs. 5%, p = 0.450). There was observeda tendency to the presence of lymph node metastases (53% vs. 34%, p = 0.182) andhigher Ki67 (> 20%) (69% vs. 46%, p = 0.209) in TP53 gene homozygotes. HER2overexpression was associated with TP53 heterozygotes, especially in the group ofpatients at the age above 50 years (33% vs. 8%, p = 0.144). A negative receptorstatus was reported more frequently in homozygotes (43% vs.21%, p = 0.340) inpatients with age below 50 years. Similarly higher histological grade G3 wasdetected more often in homozygotes in patients at the age below 50 years (80% vs.33%, p = 0.130). Conclusion: TP53 gene homozygotes and heterozygotes differfrom each other in respect of clinicopathological factors such as: histological type,lymph node metastases, higher Ki67 (> 20%), histological grade G3, ER/PR status,tumor size (T > 2), HER2 overexpression, cancer in family history and diabetes.Patient’s age was associated with the pathological characteristics of tumor.
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1. Introductionp53 is a tumor suppressor gene whose product, the p53protein, maintains DNA stability and normal cellulargrowth. It participates in regulation of cell cycle check points, DNA repair, and apoptosis. p53 remains the mostcommonly mutated gene in many human cancers andoccurs in about 50% of them. In breast cancer, the
2 Huszno et al.: TP53 gene polymorphisms and clinicopathological analysis International Journal of Cancer Therapy and Oncology
www.ijcto.org
© Huszno et al. ISSN 2330-4049
frequency of TP53 gene mutations is approximately 20%to 30%. Somatic mutations of TP53 are more frequent atthe advanced stage or in cancer subtypes withaggressive behavior (such as triple negative orHER2-amplified breast cancers).1,2 Recent data showthat breast cancer in germline TP53 mutation carriers iscommonly HER2-positive (63–83%).2 TP53 mutation isan independent marker of poor prognosis, in particularin hormone receptor-positive cases.3TP53 mutation is a high risk breast cancer associatedwith Li Fraumeni syndrome. Patients with TP53mutations have a 50% risk of developing any of theassociated cancers (including breast cancer) by the ageof 30 years and have up to 93% of lifetime cancer risk.The TP53 pathway remains largely intact in luminal Acancers but often is inactivated in the more aggressiveluminal B cancers. Basal-like tumors had a highfrequency of TP53 mutation (80%). Other investigationshave shown significant enrichment of TP53 mutations inHER2-overexpressed or ER-negative tumors.4A number of single nucleotide polymorphisms (SNPs)systematically have been identified. The most commonlystudied SNP (SNP72) is a G/C variation at the secondposition of codon 72 in exon 4, leading to Arg72 orPro72 protein variants. Sharp ethnic differences areobserved for this SNP, the Arg72 variant being moreprevalent in Caucasians, whereas the Pro72 variant ismore prevalent in Chinese and African-Americans.5,6 ThePro/Pro genotype of TP53 codon 72 appears to be anindependent prognostic marker in breast cancerpatients. This Pro/Pro genotype of TP53 codon 72 wasshown to be associated with poorer disease-freesurvival (DFS) than other genotypes (p = 0.049). Theassociation of the Pro/Pro TP53 genotype with poorerDFS was especially significant in patients who receivedadjuvant chemotherapy (p = 0.009). In contrast, amongthe patients who had received adjuvant hormonaltherapy or no adjuvant systemic therapy, TP53 codon 72genotype was not associated with DFS.7,8The aim of this study was to compare TP53 germlinegene polymorphisms (c.[215G>C]) wild – typehomozygotes GG with heterozygotes GC according toclinicopathological factors.
2. Methods and MaterialsA retrospective analysis was conducted on the medicalrecords of 87 breast cancer patients who werediagnosed and treated with chemotherapy,hormonotherapy and /or immunotherapy at MariaSklodowska-Curie Memorial Cancer Center and Instituteof Oncology, Gliwice Branch in Poland (COI).Genetic diagnostics was conducted in years 2012 – 2016.All patients gave written informed consent for geneticexamination. The patients were Caucasian women from
the southern part of Poland- Silesian region. 22% ofpatients were TP53 gene homozygotes and 78% of themwere heterozygotes. The median age at diagnosis ofpatients was 52 years (range from 32 to 76). All of themwere in good performance status (ZUBROD 0 - 1). Thecomplete characteristics of patients with regard todemographic and clinicopathological features arepresented in Table 1 and Table 2.Chemotherapy was applied to 68% of patients.Neoadjuvant chemotherapy was administered to 21(36%) women and adjuvant therapy to 38 (64%) ofpatients. Anthracycline or taxane based chemotherapywas applied to 55 (63%) and 24 (28%) of patients,respectively. 23 (26%) of them received anthracyclineand taxanes together (at the same time or taxanes afteranthracyclines). Trastuzumab was administered topatients with tumors HER2 (human epidermal growthfactor) overexpression. All women with positive steroidreceptor status (oestrogen (ER), progesterone receptor(PR)), received hormonotherapy (71% of patients).Radiotherapy was applied to 69% including all patientsafter breast preserving treatment (45%). Treatmentstrategies are presented in Table 3. The follow-up timemedian was 2.4 years (range from 3 months to 19years). In case of contralateral breast cancer the followup was counted from the date of the first diagnosis ofbreast cancer.Clinical evaluation included physical examination, bloodtest, chest X ray, mammography, ultrasound breastexam, breast MRI and tumor core biopsy. The data onthe age at onset, overweight, co- morbid conditions,menopausal status, the history of cigarette smoking,surgical procedure, disease stage according to TNMclassification, histology, estrogen and progesteronereceptor status, HER2 status and contralateral breastcancer were gathered from hospital records andpathology reports. The analysis of patients’ medicalrecords was performed according to the national lawregulation. Hormone status, HER2 overexpression andKi 67 were determined by routine immuno-histochemical techniques. Mutation profile wasassessed by RFLP-PCR technique. We evaluated thepresence of polymorphism TP53 (c.[215G>C]).Statistical analysis was carried out using STATISTICA 7software. The frequency of side effects appearance wascounted. The qualitative features were presented as thepercentage of their occurrence and evaluated withFisher test and Chi 2 test with Yates correction.Differences were considered as significant if the p valuewas ≤ 0.05.
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Table 1: Clinical characteristics of the patients under study.Risk factor TP53 homozygotes heterozygotesn % n % n %Age MedianRange 5232-76 5133-69 5232-76Hypothyroidism Yes 9 10 1 5 8 12Cardiovasculardiseases Yes 5 6 1 5 4 6HA Yes 25 29 4 21 21 31History of cancerin family: Yes 62 71 11 58 51 75History of breastcancer in family Yes 28 32 5 26 23 34Stomach cancer Yes 6 7 1 5 5 7Colorectal cancer Yes 9 10 1 5 8 12Kidney cancer Yes 5 6 3 16 2 3Lung cancer Yes 4 5 0 4 6CNS Yes 6 7 1 5 5 7Treatment chemotherapy 59 68 12 63 47 69Radiation therapy 60 69 13 68 47 69SurgeryBCT 4839 5545 910 53 3929 43hormonotherapy 62 71 13 68 49 72
Table 2: Clinicopathological characteristics of the patients according to TP53 gene polymorphisms (c.[215G>C]).Risk factor Risk factor Tp53 homozygotes Tp53 heterozygotes Pn % n %Age Median 52Range 32-76 5133-69 5232-76 0.785Menopausal status PostmenopausalPremenopausal 712 3763 2642 3862 1.00Clinical staging nodes N0N positive 910 4753 4523 6634 0.182Tumor size T3-4T1-2 118 595 1157 1684 0.450Grade G G1+2G3Missing 1063 6238 41207 6436 1.00Hormonal status NegativePositive 514 2674 1751 2575 1.00HER2 overexpression NegativePositive 163 8416 4721 6931 0.568Ki67 Ki67<20%Ki67>20%Missing 496 3169 252122 5446 0.209Triple negative YesNo 415 2179 1058 1585 0.495Luminal B type Yes 7 37 27 40 1.00Luminal A type Yes 7 37 25 37 1.00
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Table 3: Treatment strategy.Features Tp53 homozygotes Tp53 heterozygotes pn % n %Chemotherapy NeoadjuvantAdjuvant 48 3367 1730 3664 1.00Immunotherapy(Trastuzumab) YesNo 316 1684 1454 2179 0.754Hormonotherapy YesNo 136 6832 4919 7228 0.779Local treatment MastectomyBCT 910 4753 3929 5743 0.449Radiotherapy YesNo 136 6832 4721 6931 1.00
3. ResultsTwo groups of patients were compared: 19 (22%) TP53gene homozygotes and 68 (78%) heterozygotes, theresults are presented in Table 2. The median age ofpatients was 52 years (range from 32 to 76). All patientswere women. 38% of them had postmenopausal status,which was defined as age > 55 years. 11% of patientswere younger than < 40 years. There was observed atendency to the presence of TP53 homozygotes inyounger patients (21% vs. 9%, p = 0.215). There was nodifference according to median age (51 vs. 52 years, p =0.785) and menopausal status (37% vs. 38%, p = 1.00)between TP53 gene homozygotes and heterozygotes. Inthe present analysis older (> 65) was observed in 9% ofpatients. (11% of homozygotes and 9% ofheterozygotes, p = 1.00). Contralateral breast cancer wasreported in 5 (6%) of patients including 1 homozygoteand 4 heterozygotes.Cancers in family history were detected in 71% ofpatients with TP53 polymorphisms and were observedinsignificantly more often in heterozygotes than inhomozygotes (75% vs. 58%, p = 0.161). The mostfrequently reported cancers in family history were:breast cancer (32%), lymphoma (17%), colorectalcancer (10%), CNS tumors (7%), gastric cancer (7%)and lung cancer (5%). Co morbid condition wasreported in 52% of patients. Hypertension andcardiovascular diseases were observed in 29% and 6%of patients, respectively. Diabetes was detected in 5% ofwomen and 10% of patients suffered fromhypothyroidism. In our study, diabetes was observedinsignificantly more often in TP53 heterozygotes than inTP53 homozygotes (5% vs. 0, p = 0.572). There was noassociation between TP53 polymorphisms(homozygotes vs. heterozygotes) and hypertension(21% vs. 31%, p = 0.568), cardiovascular diseases (5%vs. 6%, p = 1.00) or hypothyroidism (5% vs. 12%, p =0.677).Lobular invasive and ductale invasive carcinoma weredetected in 15% and 85%, respectively. The presence oflobular invasive carcinoma was observed insignificantlymore often in homozygotes (21% vs. 13%, p = 0.468),
especially in group of patients at the age below 50 years(29% vs. 4%, p = 0.095). Tumor size (T3-T4) wasdetected in 14% of patients. Patients being TP53 geneheterozygotes had larger tumor size (T > 2) thanhomozygotes (16% vs. 5%, p = 0.450). Lymph nodemetastases were reported in 38% of patients. There wasobserved a tendency to the presence of lymph nodemetastases (53% vs. 34%, p = 0.182) in patients withTP53 gene homozygotes in comparison toheterozygotes. Ki67 > 20% was detected in 51% oftumors and was more often reported in TP53 genehomozygotes (69% vs. 46%, p = 0.209), especially in thegroup of patients at the age below 50 years (100% vs.41%, p = 0.090).Histological grade G3 was detected in 36% of tumors.There was no association between G3 grade and TP53polymorphisms (38% vs.36%, p = 1.00). In contrary, inthe group of patients at the age below 50 yearshistological grade G3 was reported more frequently inTP53 homozygotes than in heterozygotes (80% vs. 33%,
p = 0.130). HER2 overexpression was present in 28% ofwomen with insignificantly higher frequency in TP53heterozygotes in comparison to homozygotes (31% vs.16%, p = 0.253), especially in the group of patients at theage above 50 years (33% vs. 8%, p = 0.144). ER negativeor PR negative tumors was observed in 26% and 29% ofpatients, respectively. There was detected a tendency tooccur ER/PR negative tumors in TP53 homozygotes incomparison to heterozygotes but only in subgroup of thepatients at the age below 50 years (43% vs. 21%, p =0.340).All patients were TP53 polymorphisms carriers. TP53mutation distribution was found in 76% of luminaltumors (37% of luminal A, 39% of luminal B), in 28% ofHER2 amplified tumors and in 16% TNBC (triplenegative breast cancer). In the younger subgroup (< 50years) luminal B subtype was observed insignificantlymore often in heterozygotes (50% vs. 29%, p = 0.415).TNBC subtype was reported more frequently in TP53homozygotes than in heterozygotes (29% vs. 7%, p =0.171).
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Table 4: The association between clinicopathological factors and pts age.<50 years >50 yearsTp53 homozygotes Tp53 heterozygotes p Tp53 homozygotes Tp53 heterozygotes pER(-)ER(+) 3 (43%)4 6 (21%)22 0.340 2 (17%)10 12 (30%)28 0.475PR (-)PR (+) 3 (43%)4 6 (22%)22 0.340 2 (17%)10 14 (35%)26 0.301G 1-2G3 14 (80%) 166 (33%) 0.130 92 (18%) 2314 (38%) 0.293Table 4 shows the association betweenclinicopathological factors and patients age.
4. DiscussionIn this retrospective study, we analyzed the relationshipbetween TP53 gene polymorphisms (c.[215G>C])homozygotes/ heterozygotes and standardclinicopathological factors such as hormone status,human epidermal growth factor, tumor size, thepresence of lymph nodes metastases, co-morbidconditions, patients’ age, menopausal status, history ofcancer in the family and the presence of metachronousbreast cancer.The most frequent cancers observed in germline TP53mutation carriers are premenopausal breast cancer,bone and soft-tissue sarcomas, adrenal corticalcarcinomas, and CNS tumors.9 In our analysis, cancers infamily history were detected in 71% of patients withTP53 polymorphisms and were observed insignificantlymore often in heterozygotes than in homozygotes (75%vs. 58%, p = 0.161). The most frequently reported cancerin family history was: breast cancer (32%), lymphoma(17%), colorectal cancer (10%), CNS tumors (7%),gastric cancer (7%) and lung cancer (5%).Some study reported that the polymorphism in TP53(rs1042522) was associated with type 2 diabetes.10Some data suggested that p53 is involved in stressresponse, metabolism and cardiovascular functioning.p53 expression in adipose tissue is associated withinsulin resistance and subsequently with age-relatedcardiovascular disorders.11 The C/C-genotype ofrs1042522 was found to be associated with changes indiastolic blood pressure (DBP) and waist circumferenceover time.12 In our study, co morbid condition wasreported in 52% of patients. Most common werehypertension 29%, cardiovascular diseases 6%, diabetes5% and hypothyroidism 10%. Diabetes was observedinsignificantly more often in TP53 heterozygotes than inTP53 homozygotes (5% vs. 0, p = 0.572). There was noassociation between TP53 polymorphisms(homozygotes vs. heterozygotes) and hypertension(21% vs. 31%, p = 0.568), cardiovascular diseases (5%vs. 6%, p = 1.00) or hypothyroidism (5% vs. 12%, p =0.677).
In some studies the presence of mutated p53 wasassociated with patient characteristics of increased ageand postmenopausal status, and tumor characteristics ofductal morphology, higher grades and ER/PR negativity,in agreement with previous studies.13,14,15 In studyconducted by Hamaguchi et al. Pro allele of p53 codon72 (rs1042522) were more frequent in ER-positive thanER-negative breast cancer, especially in patients lessthan 50-year old.16 In our analysis there was observed atendency to the presence of TP53 homozygotes inyounger patients (21% vs. 9%, p = 0.215). There was nodifference according to menopausal status (37% vs.38%, p = 1.00) between TP53 gene homozygotes andheterozygotes. The presence of lobular invasivecarcinoma was observed insignificantly more often inhomozygotes (21% vs. 13%, p = 0.468), especially in thegroup of patients at the age below 50 years (29% vs. 4%,
p = 0.095). Similarly, Ki67 > 20% (69% vs. 46%, p =0.209) and the presence of lymph node metastases (53%vs. 34%, p = 0.182). Larger tumor size (T > 2) (16% vs.5%, p = 0.450) and HER2 overexpression (31% vs. 16%,
p = 0.253) were more often reported in heterozygotes.Similarly, ER/PR negative tumors were detected morefrequently in TP53 heterozygotes but only in thesubgroup of patients at the age above 50 years (ER 30%vs. 17%, p = 0.475; PR 35% vs. 17%, p = 0.301).TP53 mutations are the most frequent geneticalterations in breast cancer, observed in 30% of breastcarcinomas. Germline TP53 mutations carriers have aremarkable risk of developing cancer: 50% by age 30years and 90% by age 60 years.17 TP53 mutationdistribution is highly linked to molecular tumorsubtypes and is found in 26% of luminal tumors (17% ofluminal A, 41% of luminal B), in 50% of HER2 amplifiedtumors, in 69% of molecular apocrine breast carcinomasand in 88% of basal-like carcinomas.18,19 In the group ofbreast cancers women with germline TP53 mutations,approximately 63–83% of tumors are HER2 positive.20Rath et al. have identified a low prevalence of germlineTP53 mutations among women diagnosed with HER2positive breast cancers before 50 years of age.21 In ourstudy, all patients were TP53 polymorphisms carriers.TP53 mutation distribution was found in 76% of luminaltumors (37% of luminal A, 39% of luminal B), in 28% ofHER2 amplified tumors and in 16% TNBC. In youngersubgroup (< 50 years) TNBC were observedinsignificantly more often in homozygotes (29% vs. 7%,
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p = 0.170) and luminal B subtype more often inheterozygotes (50% vs. 29%, p = 0.415).
5. ConclusionTP53 gene homozygotes were characterized by lobularinvasive carcinoma subtype, lymph node metastases andhigher Ki67 (> 20%). Additionally, TP53 homozygotes atthe age below 50 years were associated with histologicalgrade G3 tumors and with ER/PR negative tumors. Incontrary, larger tumor size (T > 2), HER2overexpression, cancer in family history and diabeteswere mostly present in TP53 gene heterozygotes.Patients age was associated with the pathologicalcharacteristics of tumor.
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